Le Lézard
Classified in: Health
Subject: NEW PRODUCTS/SERVICES

Neoviva, Switzerland's first addiction clinic offering guarantee


LUCERNE, Switzerland, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Neoviva, a leading luxury rehab centre launches Switzerland's first and only assurance programme in addiction treatment. With a structured and tailored approach, Neoviva's programme addresses the unique needs of each client, blending cutting-edge therapeutic methods with comprehensive aftercare. The Neoviva Guarantee is a testament to the effectiveness of their personalised Signature Programme and reflects confidence in the programme's ability to help clients achieve sustainable recovery.

"Our track record speaks for itself, with countless success stories of lasting recovery. The Neoviva Guarantee is our way of putting action behind our words. We're so convinced of our programme's efficacy that we're willing to stand by our clients long after they leave our facility. This isn't just treatment; it's a lifelong partnership in recovery," states Fenina Erpf, CEO and Co-Founder of NEOVIVA, alongside Oliver Neubert, Founder of NEOVIVA.

Clients who complete a minimum of six weeks of Neoviva's Signature programme and adhere to the 30-week continuing care plan are eligible for the Guarantee. Should a client relapse within one year of completing the programme, they may return for up to four weeks of additional intensive treatment at no extra cost.*

Nestled on the tranquil shores of Lake Lucerne, NEOVIVA's luxury rehab facility blends world-class care with an exclusive and serene environment. Housed within a real-life hotel setting, our clinic offers the perfect balance of comfort, privacy, and discretion, ensuring a supportive space for recovery. This unique setting empowers clients with the tools and strategies needed to navigate life beyond treatment, all while immersed in the breathtaking beauty of the Swiss Alps.

About Neoviva:

Neoviva is a luxury rehab centre in Switzerland that offers personalised treatment plans for mental health and addiction treatment. With pioneering methodologies, a high staff-to-client ratio, and a commitment to profound personal transformation, Neoviva is more than a rehab centre?it is a life-changing experience for those seeking lasting recovery.

*Terms and conditions apply.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/22e5d7be-00e5-4d4c-9f88-fde0ffc48718



These press releases may also interest you

at 14:30
Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial investigating the effects of Rybelsus® (semaglutide) tablets 14 mg on reducing the risk of major adverse cardiovascular events (MACE) in adults with type...

at 13:00
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with...

at 12:55
How Medical Malpractice Cases Work in Florida: What Victims Need to Know
The Law Offices of Jason Turchin, a national personal injury firm, is educating Florida residents on how medical malpractice cases work in the state. Victims of negligent medical care may be entitled to compensation, but Florida has strict laws that...

at 11:25
Franchise FastLane Partners with MaxStrength Fitness to Propel Growth
MaxStrength Fitness, a franchise concept that provides time-efficient and productive high-intensity strength training (HIT), nutritional consultation, and post-rehabilitation experiences in a boutique studio-style gym setting, has partnered with...

at 10:30
Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025
Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic® (semaglutide) injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1, at the American College of...

at 09:00
SYNAPTIVE SALE AND INVESTMENT SOLICITATION PROCESS
Richter Inc., in its capacity as court-appointed monitor (in such capacity, the "Monitor") of Synaptive Medical Inc., ("Synaptive" or "Company") pursuant to the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA"), is...

More news about Health...


News published on and distributed by: